Malaria
📧 Sign up to get email alerts when something new happens for Malaria.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2020-04-01FDA Approved: HYDROXYCHLOROQUINE SULFATE — Supplemental Application (Creekwood Pharmaceuticals LLC)
The FDA approved Creekwood Pharmaceuticals LLC's supplemental application for hydroxychloroquine sulfate, authorizing the continued marketin…
-
FDA label_change · 2020-03-31FDA Approved: HYDROXYCHLOROQUINE SULFATE — Supplemental Application (Ipca Laboratories Limited)
FDA approved a supplemental application for hydroxychloroquine sulfate from Ipca Laboratories Limited, resulting in changes to the drug's la…
-
CLINICAL_TRIALS trial_result · 2020-03-31Clinical Trial Update: Controlled Human Malaria Infection Model for Evaluation of Transmission-blocking Interventions - Study 2 [NA]
A completed clinical trial evaluating transmission-blocking interventions using a controlled human malaria infection model in malaria falcip…
-
CLINICAL_TRIALS trial_result · 2020-03-25Clinical Trial Update: Methylene Blue Against Falciparum Malaria in Burkina Faso [Phase 2]
Phase 2 trial evaluating methylene blue for falciparum malaria completed in Burkina Faso with results posted.
-
FDA approval · 2020-02-28FDA Approved: PYRIMETHAMINE — Original Application (DR.REDDYS LABORATORIES INC)
FDA approved a pyrimethamine product from Dr. Reddy's Laboratories under an Original Application (ANDA207127), adding a generic option for t…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2020-02-20Clinical Trial Update: Optimizing Hydroxyurea Therapy in Children With SCA In Malaria Endemic Areas [Phase 3]
Phase 3 trial updating hydroxyurea therapy in children with sickle cell disease in malaria-endemic areas has completed.
-
CLINICAL_TRIALS trial_result · 2020-02-11Clinical Trial Update: Effect of Artemisinin-based Combination Therapies on Schistosomiasis on Malaria Co-infection [Phase 2]
Phase 2 clinical trial evaluating artemisinin-based combination therapies for schistosomiasis with malaria co-infection; study status comple…
-
CLINICAL_TRIALS research · 2020-01-30Clinical Trial Update: Pyronaridine-artesunate With Low Dose Primaquine for Preventing P. Falciparum Transmission [Phase 2, Phase 3]
A clinical trial evaluating Pyronaridine-artesunate with low-dose primaquine to prevent transmission of Plasmodium falciparum malaria (Phase…
-
CLINICAL_TRIALS trial_result · 2019-12-19Clinical Trial Update: Effect of Paracetamol on Renal Function in Plasmodium Knowlesi Malaria [Phase 3]
Phase 3 trial assessing the effect of paracetamol on renal function in patients with malaria (Plasmodium knowlesi).
-
FDA approval · 2019-12-13FDA Approved: QUININE SULFATE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
The FDA approved a supplemental application for QUININE SULFATE submitted by Teva Pharmaceuticals USA, Inc. This action updates the product …
-
CLINICAL_TRIALS trial_result · 2019-11-26Clinical Trial Update: Absolute BA and OZ439 PK Effect of Different OZ439 Dose Volumes and Cobicistat Co-administration Study [Phase 1]
Phase 1 study examining pharmacokinetics of OZ439 with different dose volumes and cobicistat co-administration for malaria.
-
FDA label_change · 2019-11-22FDA Approved: ATOVAQUONE AND PROGUANIL HYDROCHLORIDE PEDIATRIC — Supplemental Application (Glenmark Pharmaceuticals Inc.,USA)
FDA supplements the labeling for the atovaquone and proguanil hydrochloride pediatric product, expanding pediatric dosing and indications.
-
FDA approval · 2019-11-22FDA Approved: ATOVAQUONE AND PROGUANIL HYDROCHLORIDE — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approved a supplemental application for atovaquone and proguanil hydrochloride from Mylan Pharmaceuticals Inc.
-
CLINICAL_TRIALS trial_result · 2019-11-12Clinical Trial Update: A Study to Assess the Safety and Immunogenicity of the Malaria Vaccine, R21, Administered With and Without Matrix-M1 [Phase 1]
Phase 1 trial update evaluating safety and immunogenicity of the malaria vaccine R21 with and without Matrix-M1.
-
FDA approval · 2019-11-07FDA Approved: ATOVAQUONE — Supplemental Application (Chartwell Governmental & Specialty RX, LLC.)
FDA approved a supplemental application for atovaquone submitted by Chartwell Governmental & Specialty RX, LLC.
-
CLINICAL_TRIALS trial_result · 2019-11-06Clinical Trial Update: A Study to Assess the Safety and Immunogenicity of the Malaria Vaccine, R21, With Matrix-M1 Adjuvant [Phase 1, Phase 2]
A clinical trial update for the malaria vaccine R21 with Matrix-M1 adjuvant across Phase 1 and Phase 2 evaluating safety and immunogenicity;…
-
CLINICAL_TRIALS trial_result · 2019-10-29Clinical Trial Update: Innovative Public-private Partnership to Target Subsidized Antimalarials in the Retail Sector (Aim 2) [NA]
Clinical trial update on a public-private partnership related to subsidized antimalarials in the retail sector; study status completed with …
-
CLINICAL_TRIALS trial_result · 2019-10-28Clinical Trial Update: Phase 1/2a Trial of Pf GAP p52-/p36- Sporozoite Malaria Vaccine [Phase 1, Phase 2]
Phase 1/2a trial of a Plasmodium falciparum GAP p52/p36 sporozoite malaria vaccine was terminated; results posted in 2019.
-
CLINICAL_TRIALS trial_result · 2019-10-09Clinical Trial Update: Efficacy of GSK Biologicals' Candidate Malaria Vaccine 257049 Against Malaria Disease in Infants and Children in Africa [Phase 3]
Phase 3 trial update for GSK's malaria vaccine candidate 257049 in infants and children in Africa; results posted after completion.
-
CLINICAL_TRIALS trial_result · 2019-09-30Clinical Trial Update: Pyramax in Asymptomatic Carriers of P. Falciparum Monoinfections [Phase 2]
Phase 2 trial update for Pyramax in asymptomatic carriers of Plasmodium falciparum monoinfections; status not disclosed.
-
CLINICAL_TRIALS trial_result · 2019-09-26Clinical Trial Update: An Efficacy Study of IV Boosting With ChAd63/MVA ME-TRAP [Phase 1, Phase 2]
An efficacy study of IV boosting with ChAd63/MVA ME-TRAP for malaria completed its Phase 1 and Phase 2 trials.
-
CLINICAL_TRIALS trial_result · 2019-08-29Clinical Trial Update: Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Given at 6, 7.5 and 9 Months of Age in Co-administration With Measles, Rubella and Yellow Fever (YF) Vaccines Followed by a Booster of the Malaria Vaccine. [Phase 3]
Phase 3 trial evaluating immunogenicity and safety of GSK's malaria vaccine given with routine vaccines at 6, 7.5, and 9 months, followed by…
-
CLINICAL_TRIALS trial_result · 2019-08-28Clinical Trial Update: A Study to Evaluate the Pharmacokinetics of Oral Formulations of MMV390048 Administered Fasted to Healthy Volunteers [Phase 1]
Phase 1 pharmacokinetics study of oral formulations of MMV390048 in healthy volunteers completed; results posted in 2019.
-
CLINICAL_TRIALS trial_result · 2019-08-15Clinical Trial Update: An Extension to Study MALARIA-055 PRI (NCT00866619) to Evaluate the Long-term Efficacy, Safety and Immunogenicity of GSK Biologicals' Candidate Malaria Vaccine in Infants and Children in Africa [Phase 3]
Phase 3 trial extension evaluating long-term efficacy, safety, and immunogenicity of GlaxoSmithKline's malaria vaccine in infants and childr…
-
FDA approval · 2019-08-05FDA Approved: COARTEM — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for COARTEM (artemether and lumefantrine) submitted by Novartis Pharmaceuticals Corporation. Thi…